Literature DB >> 17474565

Potential effect of zoledronate therapy in heavy proteinuria.

N Gokden, M Zangari, F Elici, B Barlogie, J Kumar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17474565     DOI： 10.5414/cnp67263

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN： 0301-0430            Impact factor:   0.975


× No keyword cloud information.
  4 in total

1.  Nephrotic syndrome induced by pamidronate.

Authors:  M A G J ten Dam; L B Hilbrands; J F M Wetzels
Journal:  Med Oncol       Date:  2010-09-24       Impact factor: 3.064

2.  Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases.

Authors:  Murat Dincer; Kadri Altundag; Hakan Harputluoglu; Sercan Aksoy; Mustafa Cengiz; Ibrahim Gullu
Journal:  Med Oncol       Date:  2008-01-15       Impact factor: 3.064

3.  Collapsing focal segmental glomerulosclerosis resulting from a single dose of zoledronate.

Authors:  Javier A Neyra; Omkar U Vaidya; Allen Hendricks; Kamalanathan K Sambandam
Journal:  Nephron Extra       Date:  2014-10-14

Review 4.  Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine?

Authors:  Jolanta Małyszko; Leszek Kozlowski; Klaudia Kozłowska; Maciej Małyszko; Jacek Małyszko
Journal:  Oncotarget       Date:  2017-05-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.